Does the media prefer SPRY or COAG?

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 2 mentions for Hemab Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.70 beat Hemab Therapeutics' score of -0.13 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, SPRY or VCEL?

Vericel has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ARS Pharmaceuticals $98.99M 5.32 -$171.30M -$2.01 N/A Vericel $276.26M 8.52 $16.52M $0.47 97.78

Does the media favor SPRY or VCEL?

In the previous week, Vericel had 25 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 31 mentions for Vericel and 6 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.70 beat Vericel's score of 0.53 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 8 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KLRA or SPRY?

In the previous week, ARS Pharmaceuticals had 3 more articles in the media than Kailera Therapeutics. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 3 mentions for Kailera Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.70 beat Kailera Therapeutics' score of -0.33 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SPRY or NUVB?

In the previous week, Nuvation Bio had 4 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 10 mentions for Nuvation Bio and 6 mentions for ARS Pharmaceuticals. Nuvation Bio's average media sentiment score of 0.94 beat ARS Pharmaceuticals' score of 0.70 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PHVS or SPRY?

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 2 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.54 beat ARS Pharmaceuticals' score of 0.70 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ARS Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

ARS Pharmaceuticals (SPRY) Competitors

$5.32 -0.15 (-2.66%)

As of 12:04 PM Eastern

Compare

SPRY vs. COAG, VCEL, KLRA, NUVB, and PHVS

Should you buy ARS Pharmaceuticals stock or one of its competitors? MarketBeat compares ARS Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ARS Pharmaceuticals include Hemab Therapeutics (COAG), Vericel (VCEL), Kailera Therapeutics (KLRA), Nuvation Bio (NUVB), and Pharvaris (PHVS).

How does ARS Pharmaceuticals compare to Hemab Therapeutics?

ARS Pharmaceuticals (NASDAQ:SPRY) and Hemab Therapeutics (NASDAQ:COAG) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Hemab Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Hemab Therapeutics' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Hemab Therapeutics	N/A	N/A	N/A

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 2 mentions for Hemab Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.70 beat Hemab Therapeutics' score of -0.13 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ARS Pharmaceuticals currently has a consensus price target of $28.20, suggesting a potential upside of 432.08%. Hemab Therapeutics has a consensus price target of $48.00, suggesting a potential downside of 1.01%. Given ARS Pharmaceuticals' higher possible upside, equities analysts clearly believe ARS Pharmaceuticals is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Hemab Therapeutics has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$98.99M	5.32	-$171.30M	-$2.01	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A

Summary

ARS Pharmaceuticals beats Hemab Therapeutics on 7 of the 13 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Vericel?

ARS Pharmaceuticals (NASDAQ:SPRY) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

In the previous week, Vericel had 25 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 31 mentions for Vericel and 6 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.70 beat Vericel's score of 0.53 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	8 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

ARS Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Vericel has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Vericel has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$98.99M	5.32	-$171.30M	-$2.01	N/A
Vericel	$276.26M	8.52	$16.52M	$0.47	97.78

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ARS Pharmaceuticals currently has a consensus price target of $28.20, suggesting a potential upside of 432.08%. Vericel has a consensus price target of $58.40, suggesting a potential upside of 27.08%. Given ARS Pharmaceuticals' higher probable upside, equities analysts clearly believe ARS Pharmaceuticals is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Vericel has a net margin of 7.91% compared to ARS Pharmaceuticals' net margin of -200.00%. Vericel's return on equity of 6.91% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Vericel	7.91%	6.91%	5.02%

Summary

Vericel beats ARS Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and ARS Pharmaceuticals (NASDAQ:SPRY) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Kailera Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Kailera Therapeutics' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

In the previous week, ARS Pharmaceuticals had 3 more articles in the media than Kailera Therapeutics. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 3 mentions for Kailera Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.70 beat Kailera Therapeutics' score of -0.33 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kailera Therapeutics currently has a consensus target price of $42.75, suggesting a potential upside of 137.90%. ARS Pharmaceuticals has a consensus target price of $28.20, suggesting a potential upside of 432.08%. Given ARS Pharmaceuticals' higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Kailera Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A
ARS Pharmaceuticals	$98.99M	5.32	-$171.30M	-$2.01	N/A

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Kailera Therapeutics and ARS Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Nuvation Bio?

ARS Pharmaceuticals (NASDAQ:SPRY) and Nuvation Bio (NYSE:NUVB) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

ARS Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

ARS Pharmaceuticals presently has a consensus target price of $28.20, suggesting a potential upside of 432.08%. Nuvation Bio has a consensus target price of $12.88, suggesting a potential upside of 100.83%. Given ARS Pharmaceuticals' higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

ARS Pharmaceuticals has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$98.99M	5.32	-$171.30M	-$2.01	N/A
Nuvation Bio	$62.90M	35.49	-$204.63M	-$0.43	N/A

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Nuvation Bio had 4 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 10 mentions for Nuvation Bio and 6 mentions for ARS Pharmaceuticals. Nuvation Bio's average media sentiment score of 0.94 beat ARS Pharmaceuticals' score of 0.70 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio has a net margin of -102.06% compared to ARS Pharmaceuticals' net margin of -200.00%. Nuvation Bio's return on equity of -44.10% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Nuvation Bio	-102.06%	-44.10%	-23.80%

Summary

Nuvation Bio beats ARS Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and ARS Pharmaceuticals (NASDAQ:SPRY) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

ARS Pharmaceuticals has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
ARS Pharmaceuticals	$98.99M	5.32	-$171.30M	-$2.01	N/A

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Pharvaris presently has a consensus price target of $50.08, indicating a potential upside of 50.06%. ARS Pharmaceuticals has a consensus price target of $28.20, indicating a potential upside of 432.08%. Given ARS Pharmaceuticals' higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Pharvaris has a beta of -2.31, indicating that its stock price is 331% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 2 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.54 beat ARS Pharmaceuticals' score of 0.70 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ARS Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Pharvaris' return on equity of -67.56% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Summary

ARS Pharmaceuticals beats Pharvaris on 10 of the 16 factors compared between the two stocks.

Get ARS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRY vs. The Competition

Export

Metric	ARS Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$526.80M	$11.48B	$6.80B	$12.89B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	-2.64	791.51	279.90	25.40
Price / Sales	5.32	946.50	648.58	114.39
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	4.57	10.36	11.10	6.30
Net Income	-$171.30M	$2.80B	$3.48B	$347.60M
7 Day Performance	-6.53%	1.42%	1.93%	2.53%
1 Month Performance	-38.08%	-3.36%	-3.29%	-2.57%
1 Year Performance	-69.51%	154.79%	62.38%	20.26%

ARS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRY ARS Pharmaceuticals	2.5258 of 5 stars	$5.32 -2.7%	$28.20 +430.6%	-68.2%	$528.79M	$98.99M	N/A	90
COAG Hemab Therapeutics	1.7277 of 5 stars	$50.39 +6.5%	$48.00 -4.7%	N/A	$2.35B	N/A	N/A	72
VCEL Vericel	4.095 of 5 stars	$45.32 +0.6%	$55.50 +22.5%	+29.2%	$2.30B	$276.26M	107.91	300	Trending News Earnings Report Analyst Revision
KLRA Kailera Therapeutics	2.9085 of 5 stars	$17.48 -1.2%	$42.75 +144.6%	N/A	$2.26B	N/A	N/A	145
NUVB Nuvation Bio	3.7083 of 5 stars	$6.65 +3.5%	$12.88 +93.8%	+177.7%	$2.24B	$62.90M	N/A	60	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRY) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. COAG, VCEL, KLRA, NUVB, and PHVS

How does ARS Pharmaceuticals compare to Hemab Therapeutics?

Summary

How does ARS Pharmaceuticals compare to Vericel?

Summary

How does ARS Pharmaceuticals compare to Kailera Therapeutics?

Summary

How does ARS Pharmaceuticals compare to Nuvation Bio?

Summary

How does ARS Pharmaceuticals compare to Pharvaris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. COAG, VCEL, KLRA, NUVB, and PHVS

How does ARS Pharmaceuticals compare to Hemab Therapeutics?

Is SPRY or COAG more profitable?

Do institutionals & insiders hold more shares of SPRY or COAG?

Does the media prefer SPRY or COAG?

Do analysts rate SPRY or COAG?

Which has higher valuation & earnings, SPRY or COAG?

Summary

How does ARS Pharmaceuticals compare to Vericel?

Does the media favor SPRY or VCEL?

Which has more volatility and risk, SPRY or VCEL?

Which has preferable earnings & valuation, SPRY or VCEL?

Do insiders and institutionals hold more shares of SPRY or VCEL?

Do analysts rate SPRY or VCEL?

Is SPRY or VCEL more profitable?

Summary

How does ARS Pharmaceuticals compare to Kailera Therapeutics?

Is KLRA or SPRY more profitable?

Does the media prefer KLRA or SPRY?

Do analysts prefer KLRA or SPRY?

Which has better earnings and valuation, KLRA or SPRY?

Do institutionals and insiders have more ownership in KLRA or SPRY?

Summary

How does ARS Pharmaceuticals compare to Nuvation Bio?

Which has more volatility and risk, SPRY or NUVB?

Do analysts recommend SPRY or NUVB?

Which has stronger earnings and valuation, SPRY or NUVB?

Do insiders & institutionals hold more shares of SPRY or NUVB?

Does the media prefer SPRY or NUVB?

Is SPRY or NUVB more profitable?

Summary

How does ARS Pharmaceuticals compare to Pharvaris?

Which has preferable valuation & earnings, PHVS or SPRY?

Do insiders & institutionals have more ownership in PHVS or SPRY?

Do analysts rate PHVS or SPRY?

Which has more volatility & risk, PHVS or SPRY?

Does the media refer more to PHVS or SPRY?

Is PHVS or SPRY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools